Related references
Note: Only part of the references are listed.Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria
Nuntana Kasitanon et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2018)
Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study
Hung-Lin Chen et al.
JOURNAL OF RHEUMATOLOGY (2018)
Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease
M. Iudici et al.
LUPUS (2018)
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults
Alexandra Serris et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Splenectomy for immune thrombocytopenia: down but not out
Shruti Chaturvedi et al.
BLOOD (2018)
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Vittorio Pengo et al.
BLOOD (2018)
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study
Luca Iaccarino et al.
JOURNAL OF AUTOIMMUNITY (2018)
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis
Francois Chasset et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study
Francois Chasset et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study
Ioana Ruiz-Arruza et al.
ARTHRITIS CARE & RESEARCH (2018)
A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy
Marcelo De Rosa et al.
KIDNEY INTERNATIONAL (2018)
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
J. Michael Gaziano et al.
LANCET (2018)
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Louise Bowman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
2008-2018: a decade of recommendations for systemic lupus erythematosus
Dimitrios T. Boumpas et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?
Paul M. Ridker
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission
Margherita Zen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
L. Andreoli et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
Ronald van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)
A. Kuhn et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus
Michel W. P. Tsang-A-Sjoe et al.
RHEUMATOLOGY (2017)
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Serena Fasano et al.
JOURNAL OF RHEUMATOLOGY (2017)
Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine
Ji-Won Kim et al.
JOURNAL OF RHEUMATOLOGY (2017)
Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort
Cesar Magro-Checa et al.
RHEUMATOLOGY (2017)
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus
Inigo Rua-Figueroa et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile-Onset Systemic Lupus Erythematosus
Lily S. H. Lim et al.
ARTHRITIS CARE & RESEARCH (2017)
Defining Low Disease Activity in Systemic Lupus Erythematosus
Ari Polachek et al.
ARTHRITIS CARE & RESEARCH (2017)
Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid
Linda T. Hiraki et al.
ARTHRITIS CARE & RESEARCH (2017)
Validity of the Italian algorithm for the attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study
Alessandra Bortoluzzi et al.
BMJ OPEN (2017)
Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus
Renee Fruchter et al.
JAMA DERMATOLOGY (2017)
The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Mullerian Hormone
Farah Tamirou et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Predictors of incident proteinuria among patients with SLE
Ali Duarte-Garcia et al.
LUPUS SCIENCE & MEDICINE (2017)
Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)
Manuel Francisco Ugarte-Gil et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
Md Yuzaiful Md Yusof et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India
Nikhil Gupta et al.
CLINICAL RHEUMATOLOGY (2017)
Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial
Josep Ordi-Ros et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis
F. Chasset et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts
Guillermo Ruiz-Irastorza et al.
AUTOIMMUNITY REVIEWS (2017)
Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis
Emilie C. Rijnink et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Kate Franklyn et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study
A. Fanouriakis et al.
LUPUS (2016)
Repeated Renal Biopsy - A Predictive Tool to Assess the Probability of Renal Flare in Lupus Nephritis
Gaston J. Pineiro et al.
AMERICAN JOURNAL OF NEPHROLOGY (2016)
Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis
Guo-Cui Wu et al.
AUTOIMMUNITY REVIEWS (2016)
Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis
Jasvinder A. Singh et al.
BMC MEDICINE (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli et al.
EUROPEAN HEART JOURNAL (2016)
Assessment of Clinical Criteria for Sepsis For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Christopher W. Seymour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Remission and withdrawal of therapy in lupus nephritis
Gabriella Moroni et al.
JOURNAL OF NEPHROLOGY (2016)
Infection in Southern Chinese Patients with Systemic Lupus Erythematosus: Spectrum, Drug Resistance, Outcomes, and Risk Factors
Dongying Chen et al.
JOURNAL OF RHEUMATOLOGY (2016)
Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study
Konstantinos Tselios et al.
JOURNAL OF RHEUMATOLOGY (2016)
The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus
M. Taraborelli et al.
LUPUS (2016)
The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort
F. Conti et al.
LUPUS (2016)
Thrombocytopenia in Systemic Lupus Erythematosus Clinical Manifestations, Treatment, and Prognosis in 230 Patients
Jin-Hee Jung et al.
MEDICINE (2016)
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study
Michele Iudici et al.
RHEUMATOLOGY (2016)
Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period
Carmen V. Medina-Quinones et al.
ARTHRITIS CARE & RESEARCH (2016)
Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Chi Chiu Mok et al.
ARTHRITIS CARE & RESEARCH (2016)
Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: an analysis using the GOAL study
Jessica H. Knight et al.
LUPUS SCIENCE & MEDICINE (2016)
Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial
Zhihong Liu et al.
ANNALS OF INTERNAL MEDICINE (2015)
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes
Margherita Zen et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis
Ioana Ruiz-Arruza et al.
AUTOIMMUNITY REVIEWS (2015)
A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye
Nathalie Costedoat-Chalumeau et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2015)
Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus
M. Olfat et al.
LUPUS (2015)
EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres
Cristina Pamfil et al.
RHEUMATOLOGY (2015)
Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study
Artemis Koutsonikoli et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Responses to Rituximab Suggest B Cell-Independent Inflammation in Cutaneous Systemic Lupus Erythematosus
Edward M. Vital et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials Lessons Learned from the Euro-Lupus Nephritis Cohort
Maria Dall'Era et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis
Shaan Chugh et al.
LANCET HAEMATOLOGY (2015)
The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort
Manuel F. Ugarte-Gil et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ian N. Bruce et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
The clinically quiescent phase in early-diagnosed SLE patients: inception cohort study
Nuntana Kasitanon et al.
RHEUMATOLOGY (2015)
Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus
Alessandra Bortoluzzi et al.
RHEUMATOLOGY (2015)
Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years
Chee-Seng Yee et al.
RHEUMATOLOGY (2015)
Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis
Flavia Ballocca et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2015)
Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus - the Hopkins Lupus Cohort
Sarah Al Sawah et al.
LUPUS SCIENCE & MEDICINE (2015)
Lymphoma risk in systemic lupus: effects of disease activity versus treatment
Sasha Bernatsky et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus
Johanna T. Gustafsson et al.
AUTOIMMUNITY (2014)
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis
Laurent Arnaud et al.
AUTOIMMUNITY REVIEWS (2014)
Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment
Zahi Touma et al.
JOURNAL OF RHEUMATOLOGY (2014)
Cluster Analysis of Autoantibodies in 852 Patients with Systemic Lupus Erythematosus from a Single Center
Bahar Artim-Esen et al.
JOURNAL OF RHEUMATOLOGY (2014)
Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus
Amanda J. Steiman et al.
JOURNAL OF RHEUMATOLOGY (2014)
Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study
Nobuyuki Miyasaka et al.
Modern Rheumatology (2014)
Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis
Hidekazu Ikeuchi et al.
MODERN RHEUMATOLOGY (2014)
Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy
R. Sakthiswary et al.
LUPUS (2014)
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
Russell C. Dale et al.
NEUROLOGY (2014)
Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review
Tatiana Cobo-Ibanez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy
Ronald B. Melles et al.
JAMA OPHTHALMOLOGY (2014)
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study
Michael Walsh et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus
C. C. Mok et al.
ARTHRITIS AND RHEUMATISM (2013)
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials
Michelle A. Petri et al.
ARTHRITIS AND RHEUMATISM (2013)
Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus
Patricia Costa-Reis et al.
CLINICAL IMMUNOLOGY (2013)
Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study
C. C. Mok et al.
LUPUS (2013)
Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis
B. Duxbury et al.
LUPUS (2013)
Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review
Jose M. Pego-Reigosa et al.
ARTHRITIS CARE & RESEARCH (2013)
Incidence of and Risk Factors for Adverse Cardiovascular Events Among Patients With Systemic Lupus Erythematosus
Laurence S. Magder et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2012)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Susan Manzi et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
George K. Bertsias et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Use of atorvastatin in systemic lupus erythematosus in children and adolescents
L. E. Schanberg et al.
ARTHRITIS AND RHEUMATISM (2012)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts
Candido Diaz-Lagares et al.
AUTOIMMUNITY REVIEWS (2012)
Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome
J. Cortes-Hernandez et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients
W. Marder et al.
GYNECOLOGICAL ENDOCRINOLOGY (2012)
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
A. Fernandez-Nebro et al.
LUPUS (2012)
Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period
Amanda J. Steiman et al.
ARTHRITIS CARE & RESEARCH (2012)
Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre
A. Bortoluzzi et al.
REUMATISMO (2012)
Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial
Wei Chen et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2011)
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
S. van Assen et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Lupus Atherosclerosis Prevention Study (LAPS)
M. A. Petri et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Mycophenolate Mofetil for Induction Treatment of Lupus Nephritis: A Systematic Review and Metaanalysis
Zahi Touma et al.
JOURNAL OF RHEUMATOLOGY (2011)
Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus
Bryan Gammon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial
Annegret Kuhn et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: A randomized, vehicle-controlled, double-blind study
Annegret Kuhn et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
International consensus for a definition of disease flare in lupus
N. Ruperto et al.
LUPUS (2011)
Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials
Y. H. Lee et al.
LUPUS (2011)
Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies
Peggy Reiner et al.
MOVEMENT DISORDERS (2011)
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Mary Anne Dooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gonadotropin Releasing Hormone Agonists May Minimize Cyclophosphamide Associated Gonadotoxicity in SLE and Autoimmune Diseases
Zeev Blumenfeld et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2011)
Rituximab Therapy in Refractory Neuropsychiatric Lupus: Current Clinical Evidence
Javier Narvaez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2011)
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
G. Ruiz-Irastorza et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
M. Mosca et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
F. A. Houssiau et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
Frederic A. Houssiau et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
G. K. Bertsias et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Safety and Efficacy of Rituximab in Systemic Lupus Erythematosus
Benjamin Terrier et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
AGREE II: advancing guideline development, reporting and evaluation in health care
Melissa C. Brouwers et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
V. Pengo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations
George K. Bertsias et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Clinical and Serologic Correlations and Autoantibody Clusters in Systemic Lupus Erythematosus A Retrospective Review of 917 Patients in South China
Xuhua Tang et al.
MEDICINE (2010)
Prednisone, Lupus Activity, and Permanent Organ Damage
Mae Thamer et al.
JOURNAL OF RHEUMATOLOGY (2009)
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine
I. Cavazzana et al.
LUPUS (2009)
Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases
M. Ramos-Casals et al.
LUPUS (2009)
Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study
John N. Boletis et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Successful treatment of class V+IV lupus nephritis with multitarget therapy
Hao Bao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis
C. -C. Szeto et al.
RHEUMATOLOGY (2008)
EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics
G. Bertsias et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy
A. Kreuter et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus
Nathalie Costedoat-Chalumeau et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review
Cc Mok
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2007)
Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus:: results of a retrospective study in 43 patients
J Wenzel et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Pimecrolimus 1% cream for cutaneous lupus erythematosus
A Kreuter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus
YN You et al.
ANNALS OF SURGERY (2004)
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial -: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial
FA Houssiau et al.
ARTHRITIS AND RHEUMATISM (2004)
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens:: current questions and tentative answers in rheumatology
F Buttgereit et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
Immunosuppressive therapy in lupus nephritis -: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
FA Houssiau et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
